Funding Round
Magnus Medical raises $55M Series B to expand SAINT TMS protocol access
MedCity News4/10/2026·04/10/26🌐 USA
Summary
Magnus Medical secured a $55M Series B led by Foresite Capital with Ajax Health, GV, and Andreessen Horowitz Bio participating. The company will use funds to build dedicated SAINT TMS treatment centers in 15 US cities and pursue FDA clearance for their accelerated 5-day protocol, which currently operates under physician direction.
Why it matters
SAINT's 79% remission rate in treatment-resistant depression far outperforms standard TMS (30-40%). If the pivotal trial replicates this and achieves FDA clearance, SAINT centers could become the dominant outpatient treatment for severe TRD, displacing inpatient ECT.
#TMS#Depression#Mental Health Tech#USA
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in